REVERSAL1010 Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-80.
|
Atorvastatin 80 |
253 |
-46.3 |
-42.9 |
-39.1 |
-0.4 |
18 |
REVERSAL1010 Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-80.
|
Pravastatin 40 |
249 |
-25.2 |
-24.7 |
-22 |
2.7 |
18 |
ESTABLISH1111 Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110(9):1061-8.
|
Atorvastatin 20 |
35 |
-41.7 |
-35.4 |
-27.9 |
-13.1 |
6 |
ESTABLISH1111 Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110(9):1061-8.
|
Control |
35 |
-0.7 |
-1.9 |
2.4 |
8.7 |
6 |
JAPAN-ACS1212 Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54(4):293-302.
|
Pitavastatin 4 |
125 |
-36.2 |
-30.5 |
-27.6 |
-16.9 |
8-12 |
JAPAN-ACS1212 Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54(4):293-302.
|
Atorvastatin 20 |
127 |
-35.8 |
-30.1 |
-27.6 |
-18.1 |
8-12 |
SATURN1313 Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87.
|
Atorvastatin 80 |
519 |
-41.5 |
-35.9 |
-28.4 |
-4.0 |
26 |
SATURN1313 Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87.
|
Rosuvastatin 40 |
520 |
-47.8 |
-40.2 |
-30.9 |
-5.8 |
26 |
Hong et al.1414 Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, et al. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J. 2011;75(2):398-406.
|
Rosuvastatin 20 |
65 |
-49 |
-44 |
-36 |
-2.7 |
11 |
Hong et al.1414 Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, et al. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J. 2011;75(2):398-406.
|
Atorvastatin 40 |
63 |
-40 |
-35.4 |
-34 |
-1.9 |
11 |
COSMOS1515 Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, et al. COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009;73(11):2110-7.
|
Rosuvastatin 2,5-20 |
215 |
-38.6 |
-36.7 |
-31.3 |
-5.1 |
19 |
ASTEROID66 Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-65.
|
Rosuvastatin 40 |
346 |
-53.2 |
-47.2 |
-41.5 |
-6.7 |
24 |
ARTMAP1616 Lee CW, Kang SJ, Ahn JM, Song HG, Lee JY, Kim WJ, et al. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).Am J Cardiol. 2012;109(12):1700-4.
|
Atorvastatin 10-20 |
143 |
-47 |
-43.4 |
- |
-3.9 |
6 |
ARTMAP1616 Lee CW, Kang SJ, Ahn JM, Song HG, Lee JY, Kim WJ, et al. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).Am J Cardiol. 2012;109(12):1700-4.
|
Rosuvastatin 20 |
128 |
-49 |
-45.9 |
- |
-7.4 |
6 |
GAIN1717 Schartl M, Bocksch W, Koschyk DH, Voelker W, Karsch KR, Kreuzer J, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104(4):387-92.
|
Atorvastatin 20-80 |
65 |
-42 |
-41 |
- |
2.5 |
12 |
GAIN1717 Schartl M, Bocksch W, Koschyk DH, Voelker W, Karsch KR, Kreuzer J, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104(4):387-92.
|
Usual care |
66 |
-16 |
-15.9 |
- |
11.8 |
12 |
Kawasaki et al.1818 Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2005;45(12):1946-53.
|
Control |
17 |
-1.9 |
-1.1 |
- |
0 |
6 |
Kawasaki et al.1818 Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2005;45(12):1946-53.
|
Pravastatin 20 |
17 |
-31.5 |
-28.6 |
- |
-0.9 |
6 |
Kawasaki et al.1818 Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2005;45(12):1946-53.
|
Atorvastatin 20 |
18 |
-38.7 |
-39.2 |
- |
-2.4 |
6 |
Jensen et al.1919 Jensen LO, Thayssen P, Pedersen KE, Stender S, Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation. 2004;110(3):265-70.
|
Simvastatin 40 |
40 |
-46.3 |
-42.8 |
- |
-6.3 |
3-12 |
Jensen et al.1919 Jensen LO, Thayssen P, Pedersen KE, Stender S, Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation. 2004;110(3):265-70.
|
Diet |
40 |
-2.4 |
-2.1 |
- |
-0.4 |
3-12 |
Han et al.2020 Han SH, Chung WJ, Kang WC, Lee K, Park YM, Shin MS, et al. Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: comparative analysis with rosuvastatin alone by intravascular ultrasound. Int J Cardiol. 2012;158(2):217-24.
|
Rosuvastatin 20 |
21 |
-54.2 |
-44.6 |
- |
-8.5 |
9-12 |
Han et al.2020 Han SH, Chung WJ, Kang WC, Lee K, Park YM, Shin MS, et al. Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: comparative analysis with rosuvastatin alone by intravascular ultrasound. Int J Cardiol. 2012;158(2):217-24.
|
Rosuvastatin 20/Ramipril 10 |
19 |
-47.2 |
-43.6 |
- |
-11.6 |
9-12 |
STRADIVARIUS2121 Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, et al; STRADIVARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008;299(13):1547-60.
|
Placebo |
341 |
-3.2 |
-3.8 |
|
0.5 |
18 |
A-PLUS2222 Tardif JC, Grégoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, et al; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Effects of the acyl coenzyme A: cholesterolacyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004;110(21):3372-7.
|
Placebo |
154 |
1.7 |
1.9 |
-4 |
-1.2 |
24 |
AQUARIUS2323 Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, et al. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013;310(11):1135-44.
|
Placebo |
233 |
5.6 |
4.4 |
- |
-1.1 |
26 |
Tani et al.2424 Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, Takahashi H, et al. Coronary plaque regression and lifestyle modification in patients treated with pravastatin. Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol. Circ J. 2010;74(5):954-61.
|
Pravastatin 10-20 |
84 |
-11.3 |
-12.1 |
-6.4 |
-12.6 |
6 |
Nozue et al.2525 Nozue T, Yamamoto S, Tohyama S, Umezawa S, Kunishima T, Sato A, et al. Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. Am Heart J. 2012;163(2):191-9.
|
Pitavastatin 4 |
58 |
-41 |
-37.9 |
-33 |
-2.2 |
8 |
Nozue et al.2525 Nozue T, Yamamoto S, Tohyama S, Umezawa S, Kunishima T, Sato A, et al. Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. Am Heart J. 2012;163(2):191-9.
|
Pravastatin 20 |
61 |
-29 |
-26.4 |
-25.2 |
-1.4 |
8 |
Hirayama et al.2626 Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, et al. Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy. Circ J. 2009;73(4):718-25.
|
Atorvastatin 10-20 |
20 |
-36.3 |
-36.4 |
-28.4 |
-18.9 |
20 |
HEAVEN 2727 Kovarnik T, Mintz GS, Skalicka H, Kral A, Horak J, Skulec R, et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circ J. 2012;76(1):176-83.
|
Atorvastatin 80/Ezetimibe 10 |
42 |
-28.6 |
-32.3 |
-5.8 |
-2.9 |
12 |
HEAVEN2727 Kovarnik T, Mintz GS, Skalicka H, Kral A, Horak J, Skulec R, et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circ J. 2012;76(1):176-83.
|
Standard treatment |
47 |
-1.9 |
-9.2 |
7.4 |
0.7 |
12 |
CART-22828 Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Anderson TJ, Reeves F, et al; CART-2 Investigators. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis. 2008;197(1):480-6.
|
Placebo |
111 |
-6.9 |
-8.4 |
- |
-0.3 |
12 |
ENCORE II2929 Lüscher TF, Pieper M, Tendera M, Vrolix M, Rutsch W, van den Branden F, et al. Randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J. 2009;30(13):1590-7.
|
Placebo |
112 |
-11.8 |
-9.8 |
- |
-0.3 |
18-24 |
Nasu et al.3030 Nasu K, Tsuchikane E, Katoh O, Tanaka N, Kimura M, Ehara M, et al. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. JACC Cardiovasc Interv. 2009;2(7):689-96.
|
Fluvastatin 40 |
40 |
-32.3 |
-32.8 |
-27 |
-8.3 |
12 |
Nasu et al.3030 Nasu K, Tsuchikane E, Katoh O, Tanaka N, Kimura M, Ehara M, et al. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. JACC Cardiovasc Interv. 2009;2(7):689-96.
|
Control |
39 |
2.2 |
4 |
2.3 |
2.5 |
12 |
Yamada et al.3131 Yamada T, Azuma A, Sasaki S, Sawada T, Matsubara H; REACH Study Group. Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study. Circ J. 2007;71(12):1845-50.
|
Atorvastatin 10-20 |
26 |
-32.5 |
-29.8 |
-27.6 |
-1.9 |
12 |
Yamada et al.3131 Yamada T, Azuma A, Sasaki S, Sawada T, Matsubara H; REACH Study Group. Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study. Circ J. 2007;71(12):1845-50.
|
Usual care |
32 |
0 |
-1.6 |
-2.2 |
11.5 |
12 |
Tani et al.3232 Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, et al; Surugadai Atherosclerosis Regression Investigators. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol. 2005;96(8):1089-94.
|
Pravastatin 10-20 |
52 |
-14 |
-17.9 |
- |
-14 |
6 |
Tani et al.3232 Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, et al; Surugadai Atherosclerosis Regression Investigators. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol. 2005;96(8):1089-94.
|
Control |
23 |
3.6 |
2.5 |
- |
1.1 |
6 |
Yokoyama et al.3333 Yokoyama M, Komiyama N, Courtney BK, Nakayama T, Namikawa S, Kuriyama N, et al. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study. Am Heart J. 2005;150(2):287.
|
Atorvastatin 10 |
29 |
-34 |
-30.5 |
- |
-5.6 |
6 |
Yokoyama et al.3333 Yokoyama M, Komiyama N, Courtney BK, Nakayama T, Namikawa S, Kuriyama N, et al. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study. Am Heart J. 2005;150(2):287.
|
Control |
30 |
-4.4 |
-5.2 |
- |
-3.5 |
6 |
Nakayama et al.3434 Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, et al. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol. 2010;138(2):157-65.
|
Control |
25 |
-7.1 |
-4.6 |
- |
2.8 |
6 |